244 related articles for article (PubMed ID: 22563508)
1. Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma brucei.
Vincent IM; Creek DJ; Burgess K; Woods DJ; Burchmore RJ; Barrett MP
PLoS Negl Trop Dis; 2012; 6(5):e1618. PubMed ID: 22563508
[TBL] [Abstract][Full Text] [Related]
2. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
Sokolova AY; Wyllie S; Patterson S; Oza SL; Read KD; Fairlamb AH
Antimicrob Agents Chemother; 2010 Jul; 54(7):2893-900. PubMed ID: 20439607
[TBL] [Abstract][Full Text] [Related]
3. Drug resistance in human African trypanosomiasis.
Barrett MP; Vincent IM; Burchmore RJ; Kazibwe AJ; Matovu E
Future Microbiol; 2011 Sep; 6(9):1037-47. PubMed ID: 21958143
[TBL] [Abstract][Full Text] [Related]
4. Trypanocidal activity of tetradentated pyridine-based manganese complexes is not linked to inactivation of superoxide dismutase.
Steverding D; Kolosevska K; Sánchez-Moreno M
Exp Parasitol; 2018 Sep; 192():1-5. PubMed ID: 30026114
[TBL] [Abstract][Full Text] [Related]
5. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.
Mesu VKBK; Kalonji WM; Bardonneau C; Mordt OV; Blesson S; Simon F; Delhomme S; Bernhard S; Kuziena W; Lubaki JF; Vuvu SL; Ngima PN; Mbembo HM; Ilunga M; Bonama AK; Heradi JA; Solomo JLL; Mandula G; Badibabi LK; Dama FR; Lukula PK; Tete DN; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
Lancet; 2018 Jan; 391(10116):144-154. PubMed ID: 29113731
[TBL] [Abstract][Full Text] [Related]
6. A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda.
Kansiime F; Adibaku S; Wamboga C; Idi F; Kato CD; Yamuah L; Vaillant M; Kioy D; Olliaro P; Matovu E
Parasit Vectors; 2018 Feb; 11(1):105. PubMed ID: 29471865
[TBL] [Abstract][Full Text] [Related]
7. Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine.
Steverding D; Rushworth SA
Exp Parasitol; 2017 Jul; 178():45-50. PubMed ID: 28552794
[TBL] [Abstract][Full Text] [Related]
8. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
Priotto G; Kasparian S; Mutombo W; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Baudin E; Buard V; Kazadi-Kyanza S; Ilunga M; Mutangala W; Pohlig G; Schmid C; Karunakara U; Torreele E; Kande V
Lancet; 2009 Jul; 374(9683):56-64. PubMed ID: 19559476
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy.
Amilon C; Boberg M; Tarning J; Äbelö A; Ashton M; Jansson-Löfmark R
AAPS J; 2022 Mar; 24(3):48. PubMed ID: 35338410
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of trypanocidal activity of combinations of anti-sleeping sickness drugs with cysteine protease inhibitors.
Steverding D
Exp Parasitol; 2015; 151-152():28-33. PubMed ID: 25662707
[TBL] [Abstract][Full Text] [Related]
11. Trypanosoma brucei brucei: characterization of an ODC null bloodstream form mutant and the action of alpha-difluoromethylornithine.
Li F; Hua SB; Wang CC; Gottesdiener KM
Exp Parasitol; 1998 Mar; 88(3):255-7. PubMed ID: 9562432
[TBL] [Abstract][Full Text] [Related]
12. Evaluating 5-nitrofurans as trypanocidal agents.
Bot C; Hall BS; Alvarez G; Di Maio R; González M; Cerecetto H; Wilkinson SR
Antimicrob Agents Chemother; 2013 Apr; 57(4):1638-47. PubMed ID: 23335745
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6.
Baker N; Alsford S; Horn D
Mol Biochem Parasitol; 2011 Mar; 176(1):55-7. PubMed ID: 21093499
[TBL] [Abstract][Full Text] [Related]
14. High-throughput decoding of antitrypanosomal drug efficacy and resistance.
Alsford S; Eckert S; Baker N; Glover L; Sanchez-Flores A; Leung KF; Turner DJ; Field MC; Berriman M; Horn D
Nature; 2012 Jan; 482(7384):232-6. PubMed ID: 22278056
[TBL] [Abstract][Full Text] [Related]
15. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites.
Hall BS; Bot C; Wilkinson SR
J Biol Chem; 2011 Apr; 286(15):13088-95. PubMed ID: 21345801
[TBL] [Abstract][Full Text] [Related]
16. A molecular mechanism for eflornithine resistance in African trypanosomes.
Vincent IM; Creek D; Watson DG; Kamleh MA; Woods DJ; Wong PE; Burchmore RJ; Barrett MP
PLoS Pathog; 2010 Nov; 6(11):e1001204. PubMed ID: 21124824
[TBL] [Abstract][Full Text] [Related]
17. Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.
Dauchy FA; Bonhivers M; Landrein N; Dacheux D; Courtois P; Lauruol F; Daulouède S; Vincendeau P; Robinson DR
PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005125. PubMed ID: 27855164
[TBL] [Abstract][Full Text] [Related]
18. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
Priotto G; Kasparian S; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Karunakara U
Clin Infect Dis; 2007 Dec; 45(11):1435-42. PubMed ID: 17990225
[TBL] [Abstract][Full Text] [Related]
19. A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro.
Zhou L; Stewart G; Rideau E; Westwood NJ; Smith TK
J Med Chem; 2013 Feb; 56(3):796-806. PubMed ID: 23281892
[TBL] [Abstract][Full Text] [Related]
20. Mathematical modelling of polyamine metabolism in bloodstream-form Trypanosoma brucei: an application to drug target identification.
Gu X; Reid D; Higham DJ; Gilbert D
PLoS One; 2013; 8(1):e53734. PubMed ID: 23372667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
